Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)
The protein has a calculated MW of 70.2 kDa. The protein migrates as 70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human Serum Albumin, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Biotinylated Human Serum Albumin, His,Avitag (Cat. No. HSA-H82E3) is more than 90% and the molecular weight of this protein is around 64-80 kDa verified by SEC-MALS.
Loaded Biotinylated Human Serum Albumin, His,Avitag (Cat. No. HSA-H82E3) on SA Biosensor, can bind Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (Cat. No. FCM-H5286) with an affinity constant of 0.641 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
Price(USD) : $385.00
Price(USD) : $1650.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Human albumin (Hebei Da'an Pharmaceutical) | Approved | Hebei Daan Pharmaceutical Co Ltd | Mainland China | Respiratory Distress Syndrome, Adult; Fibrosis; Shock, Hemorrhagic | Hebei Daan Pharmaceutical Co Ltd | 2002-01-31 | Fibrosis; Respiratory Distress Syndrome, Adult; Shock, Hemorrhagic | Details | ||
Human albumin(Tonrol Bio-Pharmaceutical) | Approved | Mainland China | Hypovolemia | Tonrol Bio-Pharmaceutical Co Ltd | 1996-01-01 | Hypovolemia | Details | |||
Human Albumin(Guangdong Danxia) | Approved | Guangdong Danxia Biological Pharmaceutical Co Ltd | Mainland China | Hypovolemia | Guangdong Danxia Biological Pharmaceutical Co Ltd | 2012-10-30 | Hypovolemia | Details | ||
Human Albumin(Anhui Da'An) | Approved | Mainland China | Tonrol Bio-Pharmaceutical Co Ltd | 2002-01-31 | Details | |||||
Human Albumin(Huhan Nanyue) | Approved | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Mainland China | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | 1994-01-01 | Details | ||||
Albumin Human(Cis Bio International) | Approved | Cis Bio International Sa | Pulmocis | EU | Cis Bio International Sa | 2020-04-06 | Details | |||
Human albumin (Hualan Biological Engineering) | Approved | Hualan Genetic Engineering Co Ltd | Mainland China | Anemia, Hemolytic, Autoimmune; Hypoalbuminemia; Hemorrhage; Hypovolemia | Hualan Genetic Engineering Co Ltd | 1995-01-01 | Hypovolemia; Hemorrhage; Anemia, Hemolytic, Autoimmune; Hypoalbuminemia | Details | ||
20% Human albumin (Hemarus Therapeutics) | Approved | Hemarus Therapeutics | Hemalb | India | Respiratory Distress Syndrome, Adult; Nephrotic Syndrome; Hypoalbuminemia; Hypovolemia | Hemarus Therapeutics | 2015-08-01 | Hypovolemia; Respiratory Distress Syndrome, Adult; Hypoalbuminemia; Nephrotic Syndrome | Details | |
Human albumin (Guizhou Taibang Biological Products) | Approved | Guizhou Taibang Biological Products Co Ltd | Mainland China | Respiratory Distress Syndrome, Adult; Fibrosis; Shock, Hemorrhagic | Guizhou Taibang Biological Products Co Ltd | 1998-01-01 | Fibrosis; Respiratory Distress Syndrome, Adult; Shock, Hemorrhagic | Details | ||
Albumin Human (Biotest Pharma GmbH) | Approved | Biotest Pharma Gmbh | Albiomin, Albiomin 5%, Albiomin 10% | Mainland China | Hypovolemia | Biotest Pharma Gmbh | 2008-12-18 | Hypovolemia | Details | |
Human Serum Albumin (Green Cross) | Approved | Green Cross China Biological Products Co Ltd | Mainland China | Hypovolemia | Green Cross China Biological Products Co Ltd | 1998-01-01 | Hypovolemia | Details | ||
Albumin Human(Sanquin Plasma Products) | Approved | Sanquin Plasma Products Bv | Details | |||||||
Human Albumin (SK Plasma) | Approved | Sk Plasma Co Ltd | Mainland China | Sk Plasma Co Ltd | 2010-03-15 | Details | ||||
Vialebex (LFB SA/Swedish Orphan Biovitrum AB) | Approved | Lfb Biotechnologies Sas, Swedish Orphan Biovitrum Ag | France | Hypotension; Shock | null | 2013-02-01 | Hypotension; Shock | Details | ||
Ozoralizumab | PF-5230896; PF-05230896; TS-152; ATN-103 | Approved | Ablynx Nv | Japan | Arthritis, Rheumatoid | Taisho Pharmaceutical Co Ltd | 2022-09-26 | Arthritis, Rheumatoid | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Perfluoropropane human albumin microspheres(Hunan Jingda) | Phase 3 Clinical | Hunan Jingda Pharmaceutical Co Ltd | Liver Diseases | Details | |
89 Zirconium labeled GSK-3128349 | Glaxosmithkline Plc | Details | |||
Izokibep | AFB-035; ABY-035; IMG-020; IMG020 | Phase 3 Clinical | Affibody Ab | Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis | Details |
Gefurulimab | TPP-2511; ALXN-1720; CON-9978 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Myasthenia Gravis; Proteinuria | Details |
Hyperoncotic human albumin | Phase 3 Clinical | Manchester University Nhs Foundation Trust | Shock, Septic; Sepsis; Shock | Details | |
ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 2 Clinical | Numab Therapeutics Ag, Cstone Pharmaceuticals | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.